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8ABSTRACT 
Objectives:
wegener’s granulomatosis (wG) is a form of vasculitis of unknown origin with 
a predilection for the airways and kidneys. Several studies have demonstrated 
an increasing incidence of wG. with the development of treating regimens, the 
prognosis of wG has improved markedly. The aim of this study was to define 
the status of wG in Finland in 1981-2000 by evaluating its incidence, clinical 
presentation, diagnostic delay, risk of dialysis-dependent renal insufficiency and 
mortality.Variations of these parameters and factors contributing to their changes 
were also examined.
Patients and methods:
Retrospective data retrieval was performed using the Finnish hospital discharge 
register and reviewing all available hospital case reports. All patients diagnosed 
with and treated for wG in 1981-2000 were included, and their demographic and 
clinical data were recorded up till June 2005. The patients were crossed with the 
national kidney dialysis register and the national mortality statistics. Information 
about the beginning of dialysis and kidney transplantation was available until 8th 
October 2005 and about a patient’s death until 30th June 2005.
Results: 
In 1981-2000, a total of 492 patients (243 men and 249 women) were diagnosed 
with wG at a mean age of 54 years (SD 18). The incidence increased from 1.9 to 
9.3 per million per year during this period. 
The median diagnostic delay simultaneously decreased from 17 to 4 months. 
Patients presented most often with symptoms of the ear, nose and throat (ENT) 
(45%), lung (36%), musculoskeletal system (22%) and kidney (11%). Constitutional 
symptoms were present in 36% of patients at presentation. Only minor changes 
occurred in clinical presentation in 1981-2000. Initial lung involvement, presence of 
constitutional symptoms, high erythrocyte sedimentation rate (ESR) and high ELK 
scores [(number of simultaneously involved organ groups (ENT, Lung, Kidney)] 
were associated with a shorter diagnostic delay.
Medical treatment of wG patients remained very similar in the 1980s and 1990s. 
Almost 90% of patients received cyclophosphamide (CyC) medication , either 
intravenously or orally, at some point during the course of the disease. More than 
90% received glucocorticoids. Other drugs were rarely used. 
9At the time of the survey, 84  patients (17%) needed acute or chronic dialysis. 
Initial renal involvement and elevated serum creatinine values at diagnosis were 
related to an increased risk of dialysis-dependent kidney disease. In two-thirds 
of the patients, renal impairment was reversible; only one-third of patients with 
initially elevated serum creatinine values ended in dialysis, and more than one-third 
of the dialysed patients had recovered renal function.Thirty-two patients (6.5%) 
ended up with chronic (>3 months) dialysis. Nineteen patients (3.9%) received a 
kidney transplant.
Altogether 203 patients (99 men, 104 women) died before the end of June 2005. 
wG was the underlying cause of death in 37%. The crude one-year and five-year 
survival rates were 83.3% and 74.2%, respectively. The standardized mortality ratio 
for all patients was 3.43 (95% CI = 2.98 to 3.94); 4.38 (95% CI = 3.59 to 5.61) for 
women and 2.80 (95% CI = 2.28 to 3.41) for men. Older age and elevated creatinine 
level at diagnosis predicted shorter survival. ENT symptoms at presentation and 
treatment with CyC were associated with better outcome. There was no additional 
risk associated with male gender (HR= 1.11[95% CI = 0.84 to 1.47]) or with either 
of the decades (1981-1990 and 1991-2000) of the study (HR=0.89 [95% CI = 0.64 
to 1.24]).
Conclusions: 
In 1981-2000, the incidence of wG increased ca. 4.5-fold and diagnostic delay 
decreased to about one-fourth, reflecting, at least partly, increased recognition of the 
disease and improved diagnostic means. wG patients are at great risk of developing 
dialysis-dependent renal insufficiency, which is often reversible. wG patients are 
also at an increased risk of dying compared with the rest of population. During the 
20-year study period the proportion of patients treated with CyC and glucocorticoids 
did not change markedly, nor did the prognosis of wG improve. 
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TIIVISTELMä
Yleistä:
wegenerin granulomatoosi (wG) on autoimmuunitauteihin kuuluva 
verisuonitulehdus eli vaskuliitti, jonka perimmäinen syy on yhä selvittämättä, vaikka 
taudin syntymekanismi osin tunnetaankin. Verisuonen seinämän tulehdus voi johtaa 
suonen tukkeutumiseen tai seinämän repeämiseen, mitkä tapahtumat puolestaan 
voivat johtaa kudosten hapenpuutteeseen, jopa kuolioihin, tai verenvuotoihin. Eri 
vaskuliittien kliiniset ilmenemät johtuvat paljolti siitä, minkä kokoisiin suoniin 
tulehdus pääasiassa kohdistuu. wG:n verisuonisuonitulehdus kohdistuu pieniin 
ja keskisuuriin suoniin vaurioittaen useimmiten hengitysteitä ja/tai munuaisia, 
mutta lähes mikä tahansa elin tai elinryhmä voi joskus vaurioitua. 
Useissa tutkimuksissa on tullut esiin 1900-luvulla tapahtunut wG:n 
ilmaantuvuuden kasvu ja ennusteen parantuminen. Tämän tutkimuksen 
tarkoituksena oli saada yleiskuva wG:sta Suomessa vv.1981–2000. Selvitettiin 
taudin ilmaantuvuus, kliininen taudinkuva, toteamisviive, dialyysiä vaativan 
munuaisvaurion riski ja potilaiden eliniän ennuste sekä pyrittiin toteamaan 
näissä muuttujissa tapahtuneet muutokset em. aikana ja mahdolliset muutoksiin 
vaikuttaneet tekijät.  
Potilaat ja menetelmät:
Vuosien 2002-2005 aikana kerättiin kansallisista rekistereistä ja sairaaloiden 
sairauskertomuksista vv. 1981-2000 aikana diagnosoitujen wG-potilaiden tiedot 
taudinkuvasta, sairaala- ja lääkehoidoista, taudinkulusta, komplikaatioista ja 
ennusteesta. Dialyysiä ja munuaissiirtoa koskevat tiedot ulottuivat 8.10.2005 ja 
kuolleisuustiedot 30.6.2005 asti.   
Tulokset: 
Ajanjaksona 1981–2000 Suomessa diagnosoitiin 492 wG-potilasta (243 miestä ja 
249 naista) keskimääräisessä 54 vuoden iässä. Sinä aikana vuotuinen ilmaantuvuus 
miljoonaa asukasta kohti kasvoi 1,9:stä 9,3:een ja mediaani diagnostinen (toteamis-)
viive lyheni 17:stä 4 kuukauteen.
Tavallisimmin (45 %:ssa) korva-nenä-kurkku (KNK) – elinryhmä antoi taudin 
ensimmäiset oireet, mutta myös varsin usein wG alkoi keuhkoista (36 %), tuki- ja 
liikuntaelimistä (22 %) tai munuaisista (11 %). Taudin alussa 36 %:lla potilaista 
esiintyi yleisoireita kuten lämpöilyä, väsymystä, voimattomuutta, laihtumista tms. 
Tutkimuksen käsittämien 20 vuoden aikana wG ilmaantui hyvin samanlaisin oirein. 
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Potilaat, joilla todettiin keuhkojen vaurio taudin alussa, joilla esiintyi yleisoireita, 
korkea lasko ja/tai useamman elinryhmän samanaikainen sairastuminen, 
diagnosoitiin lyhyemmällä viiveellä kuin muut.
1980- ja 1990-luvuilla wG-potilaita lääkittiin hyvin samantapaisilla lääkehoidoilla. 
Melkein 90 % potilaista sai jossain sairautensa vaiheessa syklofosfamidia (CyC) joko 
suun kautta tai suonensisäisesti. Glukokortikoideja sai yli 90 % potilaista. Muut 
lääkkeet olivat harvoin käytettyjä. 
Seurannan aikana 84 (17 %) potilasta joutui dialyysiin. Dialyysiin joutumista 
ennusti taudin alun munuaisvaurioon sopivat laboratoriolöydökset, etenkin 
diagnoosiajankohtana suurentunut seerumin kreatiniiniarvo (S-krea).  Vaikka 150 
potilaalla S-krea oli koholla diagnoosivuonna, vain 61 heistä joutui dialyysiin. 32 
potilaalla dialyysi kesti yli 3 kk (=krooninen dialyysi). 19 potilasta (3,9 % kaikista 
wG-potilaista) tarvitsi munuaissiirteen.
Kesäkuun 2005 loppuun mennessä kuoli 203 potilasta, 99 miestä ja 104 
naista. Peruskuolinsyyksi oli merkitty 37 prosentissa itse wG. yksi- ja viisivuotis-
elonjäämisosuudet olivat 83,3 % ja 74,2 %. Kaikkien wG-potilaiden standardoitu 
kuolleisuussuhde (SMR) oli 3,43.  Naisten SMR (4,38) oli suurempi kuin 
miesten (2,80). Lyhyempää eloonjäämistä ennusti korkeampi sairastumisikä ja 
diagnoosiajankohdan suurentunut S-krea – arvo. Sitä vastoin paremmin selvisivät 
potilaat, joiden oireet alkoivat KNK-elinryhmästä. Myös syklofosfamidihoito liittyi 
parempaan ennusteeseen. Eri sukupuolten ennusteet eivät eronneet toisistaan, 
ei myöskään eri vuosikymmeninä (1981–1990 ja 1991–2000) sairastuneiden 
potilaiden.
Johtopäätökset:   
Vuosina 1981–2000 wG:n ilmaantuvuus 4½-kertaistui ja toteamisviive 
supistui suunnilleen neljännekseen. Kyseiset muutokset johtunevat ainakin 
osittain lääkäreiden paremmasta wG- tietoisuudesta sekä paremmista 
toteamismenetelmistä. Vaikka 70-luvulla kehitetyt hoidot paransivat dramaattisesti 
ennustetta, yhäkin wG-potilaalla on merkittävä dialyysiin ja munuaissiirtoon 
johtavan munuaisten vajaatoiminnan riski kuten myös merkittävää ylikuolleisuutta 
muuhun väestöön verraten. Tutkimuksen 20-vuotisjakson aikana hoidot pysyivät 
hyvin samanlaisina eikä ennuste merkittävästi muuttunut. 
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1. INTRODUCTION 
wegener’s granulomatosis (wG) belongs to a group of immune-mediated 
inflammatory diseases that affects 2-5% of the population. These are chronic 
diseases which, when untreated, often progress and lead to pronounced morbidity 
and mortality. In vasculitides, immune process damages blood vessels, leading to 
obstructions, dilatations or ruptures of the vessels. These damages in turn translate 
into symptoms and signs of ischaemia and/or haemorrhage. The clinical picture of 
vasculitis depends on the calibre and location of the vessels affected and the type 
of vascular damage. The classification of vasculitides is based primarily on the size 
of the vessels affected (Table 1).  
Table 1. classification of vasculitides.
Large-vessel vasculitis
takayasu arteritis
giant-cell arteritis
Medium-sized vessel vasculitis
Polyarteritis nodosa
kawasaki disease
isolated central nervous system vasculitis
Small-vessel vasculitis
churg-strauss syndrome ANCA-
Wegener’s granulomatosis related
Microscopic polyangiitis vascu-
drug-induced anca-associated vasculitis litides
henoch-schönlein purpura
essential cryoglobulinemic vasculitis
hypersensitivity vasculitis
vasculitis due to connective tissue disorders
vasculitis due to viral infections
Paraneoplastic small-vessel vasculitis
anca= anti-neutrophil cytoplasmic antibodies
Information adapted from Jennette et al.(1997).
Four of the small-vessel vasculitides—Churg-Strauss syndrome (CSS), wG, 
microscopic polyangitis (MPA) and drug-induced anti-neutrophil cytoplasmic 
{
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antibody (ANCA)-associated vasculitis—form the group of ANCA-related 
vasculitides. The presence of anti-neutrophil cytoplasmic antibodies is a common 
feature in these vasculitides (Jennette et al. 1997).  wG is mainly associated with 
the presence of cytoplasmic ANCA (c-ANCA), which is similar to ANCA directed 
against proteinase 3 (PR3; PR3-ANCA). PR3-ANCA is seen in the sera of 66% of wG 
patients and MPO-ANCA in 24% (Kallenberg 2008).  The other small-vessel ANCA-
vasculitides (CSS, MPA and  drug-induced ANCA-associated vasculitis) present 
mostly with perinuclear ANCA (p-ANCA), which is similar to ANCA directed against 
myeloperoxidase (MPO-ANCA) (Franssen et al. 2000, Gomez-Puerta et al. 2009). 
Differences in clinical presentation exist between PR3-ANCA- and MPO-ANCA- 
associated vasculitides. PR3-associated wG develops granulomatous inflammation 
of the airways, while MPO-associated MPA shows a predilection for renal necrotizing 
vasculitis. PR3-ANCA is also associated with faster decline of renal function and 
more frequent relapses (Kallenberg 2011) (Table 2).
 This year, a recommendation for a new name for wG was presented. The present 
trend is to abandon eponyms and apply a more disease-descriptive or aetiology-
based nomenclature. Accordingly, the new name for wG would read granulomatosis 
with polyangiitis (wegener’s), which can be abbreviated as GPA. Later on, the 
information in the parentheses can be omitted (Falk et al. 2011).
Table 2. Features of the three most important anti-neutrophil cytoplasmic antibody vasculitides.
vasculitis incidence/
million/yr
granuloma-
tous inflamma-
tion of airways
lung 
haemorrhage
necrotizing 
renal vasculitis
10-year 
survival, %
sMR
CSS 0.9-2.7 + (+) (+)
WG 7.9-9.8 + + + 65-75 1.77
MPA 2.4-10.1 (+) + + 43-55 3.95
css = churg-strauss syndrome  
Wg = Wegener’s granulomatosis  
MPa = Microscopic polyangiitis    
 
information adapted from gordon et al. (1993), luqmani et al. (2001) and  
Mohammad et al. (2009). 
Differentiation between MPA and wG can be achieved based on clinical picture, 
laboratory tests (e.g. ANCA subsets) and histology. Both are hazardous diseases and 
diagnosis calls for rapid interventions. CSS presents with asthma and pronounced 
eosinophilia, features which usually differentiate it from the other ANCA vasculitides. 
Goodpasture disease presenting with rapidly progressive renal failure and sometimes 
even with severe lung hemorrhage can be differentiated from ANCA vasculitides by 
detection of anti-glomerular basement membrane antibodies.wG is a vasculitis of 
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small and medium-sized vessels, and its clinical features include granulomatotic 
vasculitis with a predilection for upper and lower airways along with necrotizing 
vasculitis producing e.g. glomerulonephritis. Dispite these organ predilections, wG 
can affect virtually any organ or organ system. 
Dispite increasing knowledge, the aetiology of wG remains unclear. wG is known 
to be an immune-mediated disease, but the precise mechanism of its aetiopathogenesis 
is incompletely understood. Having had no proper diagnostic criteria, researchers 
have used the American College of Rheumatology (ACR) classification criteria for 
vasculitides 1990 (Leavitt et al. 1990, Table 3) and the Chapel Hill classification criteria 
1994 (Jennette et al. 1994, Table 4) as substitutes. This has led to some incoherency 
among the studies, and interpretation and comparison of results has been unreliable, 
if not impossible. Propositions for diagnostic criteria of wG have been tendered only 
recently (Sorensen et al. 2000, watts et al. 2007, Tables 5 and 6).
wG has been considered a very rare disease and is still uncommon, although 
increasing incidences have been presented in the literature, most prominently in 
Norway and Sweden (Koldingsnes et al. 2000, Knight et al. 2006). The lack of 
diagnostic criteria and the wide variety in clinical presentation of wG have often 
rendered diagnosis challenging, leading to long diagnostic delays. 
Since the introduction of cyclophosphamide (CyC) and glucocorticoid to treat 
wG and other vasculitides (Fauci et al. 1973), the prognosis of patients has improved 
markedly. This study was designed to depict the features of wG patients diagnosed 
in Finland in 1981-2000. The period of 20 years was chosen as sufficiently long to 
show any changes in epidemiology, diagnostics, treatment and prognosis of wG. 
The register follow-up extended to 30 June 2005 in order to calculate 5-year survival 
rates for all patients.
Table 3. the american college of Rheumatology criteria for the classification of Wegener’s granulomatosis 
(leavitt et al. 1990).
(1) nasal or oral inflammation
development of painful or painless oral ulcers or purulent or bloody nasal discharge
(2) abnormal chest radiograph
chest radiograph showing the presence of nodules, fixed infiltrates, or cavities
(3) urinary sediment 
Microhaematuria (> 5 red blood cells per high-power field ) or red cell casts in urine 
sediment
(4) granulomatous infiltration on biopsy 
histological changes showing granulomatous inflammation within the wall of an artery 
or in the  perivascular area (artery or arteriole)
Two criteria required for classification of WG with a sensitivity of 88.2% and  
a specificity of 92.0%. 
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Table 4. chapel hill consensus conference criteria for the classification of Wegener’s granulomatosis 
(Jennette et al. 1994).
(1) small-vessel vasculitis
and
(2) granulomatous inflammation involving the upper and lower respiratory tract, and 
necrotizing vasculitis affecting small to medium-sized vessels
and
(3) necrotizing glomerulonephritis is common
Table 5. sorensen diagnostic criteria for Wegener’s granulomatosis (sorensen et al. 2000).
(1) Biopsy or surrogate parameter† for granulomatous inflammation in the respiratory system 
and
(2) Biopsy verified necrotising vasculitis in small to medium sized vessels or biopsy/surrogate 
parameter†  for glomerulonephritis or positive PR3-anca test 
and
(3) lack of eosinophilia in blood and biopsy samples.
 
 
† Surrogate parameters
Organ involvement Surrogate parameters
glomerulonephritis Proteinuria and haematuria with red blood casts
arteritis angiographic or ultrasonic demonstration of aneurysms or 
stenoses in arteries provided the patient demonstrated other 
signs of vasculitis
granulomatous inflammation in 
lower airways
Radiologically demonstrated pulmonary infiltrates or 
cavitations of more than one month’s duration provided that 
all other causes, such as infections and malignancies, were 
ruled out
granulomatous inflammation in 
upper airways
Bloody nasal discharge and/or crusting of more than one 
month’s duration; chronic sinusitis, otitis and/or mastoiditis 
(proved by radiograph, ct or MRi); cranial bone and/or 
cartilage destruction; acute hearing loss, without signs of 
traumatic disease  
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Table 6. Watts diagnostic criteria for Wegener’s granulomatosis (Watts et al.2007).
a clinical diagnosis must first be made and where possible the patient followed for a minimum of 
3 months.  
the patient must be aged ≥16 years at the time of diagnosis. 
 
 
 
the following three criteria must be fulfilled before classification:  
(a) symptoms and signs characteristic or compatible with diagnosis 
(B) at least one of the following:
 – histological proof of vasculitis 
 – Positive serology for anca 
 – specific investigations strongly suggestive of vasculitis and/or granuloma 
 – eosinophilia (>10% or >1.5 x109/l)
(c) no other diagnosis to account for symptoms/signs. 
 
 
Surrogate markers for Wegener’s granulomatosis (granulomatous disease) refer to symptoms 
suggestive of granulomatous disease affecting the upper and lower respiratory tract (in all cases 
other causes must be excluded):
lower airways
 – x-ray evidence of fixed pulmonary infiltrates, nodules or cavitations present for >1 month
 – bronchial stenosis 
upper airways
 – bloody nasal discharge and crusting for >1 month, or nasal ulceration
 – chronic sinusitis, otitis media or mastoiditis for >3 months
 – retro-orbital mass or inflammation (pseudotumour)
 – subglottic stenosis
 – saddle nose deformity/destructive sinonasal disease 
only one surrogate marker is necessary to support a diagnosis of Wegener’s granulomatosis 
surrogate markers for renal vasculitis (glomerulonephritis) are either
 – haematuria associated with red cell casts or 
 – 10% dysmorphic erythrocytes or 
 – 2+ haematuria and 2+ proteinuria on urinalysis
17
2. REVIEW OF THE LITERATURE
The granulomatous vasculitis that used to be called wegener’s granulomatosis 
[recent recomendation: granulomatosis with polyangitis (wegener)] was initially 
described by Klinger in 1931. He considered it to be a special form of polyarteritis 
nodosa (Klinger 1931). Friedrich wegener, a German pathologist and a friend 
of Klinger’s, presented in 1936 the classical triad of this disease consisting of 
granulomatous inflammation in the upper and lower airways, systemic vasculitis 
and local necrotizing glomerulonephritis (wegener 1936). 
2.1 EpidEMioLogy
Since its introduction in the 1930s, wG has become better known, and increasing 
incidences have been reported in the last few decades. Carruthers et al. (1996) found 
the annual incidence of wG to be 8.5 per million in Norfolk (UK) in 1988-1993, a 
higher rate than those previously published. Knight et al. (2006) reported a 3.6-
fold rise in the annual incidence (from 3.3/ million to 11.9/ million) in 25 years. 
Koldingsnes et al. (2000) also presented a 2.3-fold rise (from 5.2/ million to 12.0/ 
million) in 15 years. watts et al. (2000) reported a slowly increasing annual incidence 
of primary systemic vasculitides and, accordingly, of wG, similar to Gonzalez-Gay 
et al. (2003). Some studies have not, however, demonstrated rising incidences of 
wG (watts et al. 2001, Reinhold-Keller et al. 2005, watts et al. 2009) (Table 7).The 
incidence of wG in Finland in 1990 was 2.8/million/year of the adult population 
(Kaipiainen-Seppänen et al. 1996).  
Besides increasing incidences, several studies have described increasing age 
at  diagnosis of wG. Studies from the 1950s to the 1980s reported the mean age 
at onset to be 40-50 years (Kelley et al. 1993, Littlejohn et al.1985, Hunder et al. 
1990). Reinhold-Keller et al. (2005) and Knight et al. (2006) found a median age 
of about 60 years at diagnosis. The incidence has been reported to peak around 
the age of 70 years (Koldingsnes et al. 2000, watts et al. 2000, Lane et al. 2005). 
Contrarily, several studies have described the age at diagnosis to be more or less 
stable throughout the survey period (Koldingsnes et al. 2000, Reinhold-Keller et 
al. 2005, Knight et al. 2006).
 In some studies, wG has been found to be more common in Northern countries 
(watts et al. 2004, Lane et al. 2005) and among people of Caucasian descent (Jagiello 
et al. 2005, Mahr et al. 2006). Seasonal variations in the incidence have occasionally 
been reported (Raynauld et al. 1993, Carruthers et al. 1996), whereas others have 
failed to find these variations (Duna et al. 1998, Koldingsnes et al. 2000) (Table 7).
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2.2. CLiNiCAL piCturE
In wG, at least two kinds of disease processes are involved: 
1. granulomatous inflammation, mostly confined to airways; and 
2. necrotizing vasculitis, e.g., of the kidney.
The clinical picture of wG is highly variable. The following features are the most 
common (Fan et al. 1980, Savage et al. 1997, Burmester et al. 2003, Shoenfeld et 
al. 2008):
– ENT symptoms and signs: *nasal stuffiness, crusty, bloody or purulent 
nasal discharge, sinusitis,otitis, pain and inflammatory signs in the pharynx 
or larynx.
– pulmonary symptoms and signs: *cough, haemoptysis, abnormal chest 
x-ray findings or lung infections such as pneumonia or bronchitis
– renal symptoms and signs: *haematuria, proteinuria, elevated serum 
creatinine values
– musculoskeletal: *arthralgia, myalgia, arthritis
– ophthalmic: *conjunctivitis, scleritis, episcleritis, uveitis, proptosis
– indications of generalized inflammatory disease: *malaise, fatigue, 
fever, weight loss.
2.2.1. CLiNiCAL piCturE At prESENtAtioN 
wG often starts as a limited disease. The organ group most often involved at 
presentation is ENT (60-80%). Very frequently, in ca. 60% of cases, patients 
present with musculoskeletal symptoms and signs, such as arthralgias, arthritides 
and muscle aches and pains. Kidney (54%), lung (55%), eye (40%) and skin (21%) 
are fairly often involved at presentation (Table 8).
2.2.2. CLiNiCAL piCturE duriNg CourSE of thE diSEASE
Occasionally, the disease remains limited to one organ group, e.g. ENT, but most 
patients develop a more extended disease. when the disease becomes more 
generalized, constitutional symptoms and signs grow more prominent. Fever, 
malaise and weight loss are frequent complaints. In the course of the disease, ENT 
is involved in over 90% of cases, and the kidney and lung in ca. 70%. Often the 
disease proceeds to simultaneously involve all organs of the ELK concept (ENT, 
Lung, Kidney) (DeRemee et al. 1976). Virtually any organ in the body can be afflicted 
by the disease (Shoenfeld et al 2008; Table 8). 
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Fibromyalgia-like symptoms, including sleep disorders and depression, have been 
found to be more frequent in patients with wG than in the general population, 
irrespective of disease activity, damage or duration. These symptoms, whether they 
be a consequence of the disease itself or its treatment, limit the patient’s daily 
activities and reduce quality of life (Hajj-Ali Raet et al. 2011).
3.3. AEtiopAthogENESiS
Although the aetiology of wG is unknown, some theories have been presented. wG 
is one of many immune-mediated inflammatory diseases caused by failure of self-
tolerance or of regulation of the inflammatory process (Huang et al. 2001). These 
phenomena may, in turn, result from immune responses against self-antigens or 
microbial antigens. Some evidence has emerged that genetic factors, infections, 
environmental exposures and drugs can contribute to the breakdown of self-
tolerance, and thus, be connected to the risk of developing wG (Dolman et al. 
1993, Somer et al. 1995, George et al. 1997, Duna et al. 1998, Huang et al. 2001, 
Jagiello et al. 2005a, Hogan et al. 2007, Knight et al. 2010).  
3.3.1. iMMuNoLogiCAL MEChANiSMS
The immunopathological mechanisms in the development of the inflammatory 
process in wG are not altogether clear. As in other immune-mediated diseases, 
the pathogenesis of wG is considered to be connected to a failure of self-
tolerance. Proteinase 3 (PR3), as an autoantigen, obviously has a pivotal role. This 
enzyme is normally inaccessible to antibodies in azurophilic granules of resting 
polymorphonuclear leukocytes (PMNs). Some noxious agent, e.g., an inhaled 
precipitant, causes an inflammatory reaction in mucosal cells with secretion of 
pro-inflammatory cytokines. This, in turn, leads to the development of adhesion 
molecules on PMNs and endothelial cells (ECs), and PR3 is translocated to the cell 
surface. PR3 activates protease-activated receptor-2 (PAR-2), leading to maturation 
of immature dendritic cells. Mature dendritic cells, in turn, activate T-cells, which 
induce development of B-cells into ANCA-producing plasma cells. PMNs adhere to 
ECs and, due to the PR3-ANCA  binding reaction, begin to activate and degranulate. 
This leads to endothelial damage and to necrotizing vasculitis (Burmester et al. 
2003, Csernok et al. 2008a,b) (Figure 1).PR3-ANCA is mostly associated with 
granulomatous vasculitis and relapsing disease, whereas MPO-ANCA is associated 
with necrotizing vasculitis without granuloma formation (Kallenberg et al. 2008). 
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Figure 1. The gate-way receptor model : in Wg expression of PR3 in the extracellular space is increased. PR3 
stimulates the expression of PaR-2 on dc and activates PaR-2 resulting in maturation of dc, as indicated 
by expression of cd80, cd83, cd86 and hla-dR and these PR3-maturated dcs stimulate cd4+ t cells 
to generate increased expression of iFn-γ. hypothetically, t-cell activation by PR3-maturated dcs may 
finally promote the development of B-cells towards anca-producing plasma cells. [Csernok E, Holle JU, 
Gross WL. Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity 
in Wegener’s granulomatosis. Clin Exp Rheumatol 2008 May-Jun;26(3 Suppl 49):S112-7, with permission]. 
PR3= proteinase 3, PaR-2= protease-activated receptor-2, dc= dendritic cell, iFn-γ= interferon-
gamma, Mhc= major histocompatibility complex, idc= immature dendritic cell, mdc= mature 
dendritic cell, tcR= t-cell receptor.
Pendergraft et al. (2004) recently found that patients with autoimmune disorders 
had, besides antibodies to autoantigens, antibodies to proteins coded by the 
antisense  strands of the very DNA coding the autoantigen. The authors proposed 
a theory that these antisense or complementary proteins could elicit antibody 
formation. These antibodies, in turn, could elicit anti-idiotypic antibody formation. 
These  anti-idiotypic antibodies could react with autoantigens, thus  provoking an 
autoimmune disease. The immune response against PR3 in wG may be initiated 
by responses against anti-sense PR3. Complementary PR3 (cPR3) also resembles 
some microbial antigens, which may explain the alleged aetiological role of microbes 
(e.g. Staphylococcus aureus) in the pathogenesis of wG (Pendergraft et al. 2004, 
Bruner et al. 2010, wilde et al. 2011).
A recent discovery of autoantibodies against lysosomal membrane protein-2 
(LAMP-2) in patients with ANCA-associated glomerulonephritis, even in the absence 
of PR3- or MPO-ANCA, has contributed a piece to the puzzle of the aetiology of 
ANCA-associated vasculitis (AAV). Patients with localized AAV generally do not have 
anti-LAMP-2 antibodies, whereas patients with glomerulonephritis do. Moreover, 
anti-LAMP-2 cross-react with FimH, an adhesin molecule of some Gram-negative 
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pathogenic bacteria; this could be another potential explanation for microbe-related 
aetiology (Kain et.al. 2008).
Although AAV has been considered pauci-immune, i.e. lacking immune 
complexes or complement factors, evidence for the role of complement in the 
inflammatory process of AAV has mounted (wilde et al. 2011).
In AAV, T-cell subsets have their roles in pathogenesis. Elevated quantities of 
effector memory T-cells (Tems) have been demonstrated in wG. These T-cells also 
seem to be major effectors in granuloma formation and in the autoimmune process 
in wG (Lamprecht et al. 2006, wilde et al. 2009). Recent studies have shown 
functional impairment of regulatory T-cells (Tregs) in wG (Abdulahad et al. 2007, 
Morgan et al. 2010). It can be speculated that lack of regulation leads to Tems 
expansion and persistent T-cell activation (wilde et al. 2011). 
Recent findings suggest that granulomas are in fact tertiary lymphoid organs 
(TLOs). They develop in several chronic inflammatory conditions such as rejection 
of organ transplants or autoimmune diseases. These TLOs resemble secondary 
lymphoid organs (SLOs, e.g. lymph nodes) in many ways; they have similar layer 
organization of T-cells, B-cells and dendritic cells. Autoantigen presentation and 
production of ANCA are proposed to take place in these TLOs. In TLOs, lymph flow 
and antigen-presenting cell trafficking are less organized than in SLOs. This may 
result in chronic non-physiological T-cell activation and persistent autoimmune 
inflammation (Aloisi et al. 2006, wilde et al. 2011).
Though granulomas seldom exist in AAV related glomerulonephritis, some 
lymphoid neogenesis with DC-T-cell aggregates has been observed in renal 
biopsies. Hypothetically, activation of effector T-cells and stimulation of the 
immune response take place, possibly locally attenuated by Tregs (wilde et al. 
2011). In glomerulonephritic kidneys of AAV, formation and deposition of neutrophil 
extracellular traps (NETs), containing such cytoplasmic proteins as PR3, MPO 
and elastase, have been found. NET formation is associated with defence against 
microbial invaders (Brinkmann et al. 2004), but probably also has a role in 
autoimmunity leading to AAV (wilde et al. 2011).   
One example of an agent initiating the primary inflammatory process is the 
mechanism of silica exposure in the development of small-vessel vasculitis (SVV). 
Crushing silica yields radicals that react with water to produce hydroxyl radicals. 
Once absorbed into tissue, silica is not metabolized or destroyed by macrophages, 
which leads to the production of chemokines, inflammatory cytokines and growth 
factors, and these ongoing effects likely contribute to an immune-modulating 
defect.  Silica particles might, through the release of reactive oxygen radicals and 
inflammatory cytokines, trigger immunopathological mechanisms. Other factors, 
such as genetic predisposal, probably also contribute (Moulin et al. 2004, Csernok 
et al. 2006, Novick et al. 2006, Hogan et al. 2007, de Lind van wijngaarden et al. 
2008). 
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2.3.2. gENEtiC fACtorS  
Some evidence of genetic susceptibility to systemic vasculitides exists. Family clusters 
have been described (Muniain et al. 1986, Knudsen et al. 1988, Hay et al. 1991, Stoney 
et al. 1991). wG patients with thyreoiditis and relapsing polychondritis have been 
reported, suggesting a role of genes in susceptibility to autoimmune diseases (Small 
et al. 1980, Masor et al. 1994). T-cell function–associated genetic factors predisposing 
to granulomatous inflammation (HLA DPB1*0401) and PR3-ANCA seropositivity 
(PTPN22*620w) have been determined.  Haplotype DPB1*0401/RXRB03 showed 
a very strong association with wG (OR=6.41) (Jagiello et al. 2004 & 2005a,b)
Several gene loci have been connected to the risk and pathogenesis of wG. 
These include HLA-genes associated with MHC class II function (Szyld et al. 2006) 
and intracellular tyrosine phosphatase as well as alpha-1-antitrypsine and PR3 
expression on the cell surface (Jagiello et al. 2005).
2.3.3. iNfECtioNS  
Davies et al. (1982) suspected group A arbovirus to be an aetiological factor in 
segmental necrotizing glomerulonephritis. Finkel et al. (1994) reported serological 
evidence of persistent infection by Parvovirus B 19 in vasculitis patients, and 
discussed the aetiological connection. Several bacteria (e.g. Klebsiella aerogenes, 
Staphylococcus aureus, Haemophilus influenzae, and Bacillus subtilis) have been 
speculated to promote relapses of wG or even start the disease process (Pinching 
et al. 1980).  The evidence concerning Staphylococcus aureus has been most 
convincing. Preceding Staphylococcus infection could trigger the onset of wG, and/
or chronic nasal carriage could maintain disease activity (Pinching et al. 1980, 
Stegeman et al. 1994, Somer et al. 1995, George et al. 1997) (Table 9).
2.3.4. ENviroNMENtAL ExpoSurES 
wG is more common in northern countries than in southern countries (watts et al. 
2001, Lane et al. 2005). This has led to assumptions that environmental strain on 
airways, such as cold air and more abundant viral airway infections during Nordic 
winters, could be an aetiopathological mechanism of wG. If this were true, seasonal 
differences in the onset of wG should also exist. Results on this topic have, however 
been contradictory (Raynauld et al. 1993, Carruthers et al. 1996, Duna et al. 1998, 
Koldingsnes et al. 2000). 
Exposure to silicon compounds has been known to be hazardous to the lungs. 
Nuyts et al. (1995) observed that inhalation of silicon-containing compounds 
produced a nearly sevenfold risk of wG, and Hogan et al. (2007) reported especially 
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long-standing silica exposure to be a risk of evolving ANCA-associated small-vessel 
vasculitis (SVV). Observations also indicate that occupational exposure to silicon 
compounds poses a risk of developing renal disease (Kallenberg et al. 1995, de Broe 
et al. 1996). Duna et al. (2008) investigated the relationship of wG with exposure 
to fumes and particulate materials as well as pesticides. Their study suggested risk 
relationships, although the results were not conclusive. Knight et al. (2010) found no 
clear occupational risk factors for wG in their recent case-control study in Sweden. 
Table 9. infectious agents with possible aetiological impact on Wegener’s granulomatosis
Reference infectious agent clinical association
Pinching et al. (1980) Bacterial infections Role in relapses of  Wegener’s granulomatosis
davies et al. (1982) arbovirus group a segmental necrotising  glomerulonephritis  
el-Roiey et al. (1987) klebsiella pneumoniae
klebsiella infection in 
connection with autoantibody 
production 
Finkel  et al. (1994) Parvovirus B 19
chronic virus infection in 
patients with  polyarteritis 
nodosa  and  of  Wegener’s 
granulomatosis
Pinching et al. (1980)
staphylococcus aureus
Preceding infection or chronic 
nasal carriage/ triggering 
the disease process and/
or maintenance of disease 
activity
stegeman et al. (1994)
george et al. (1997)
Pudifin et al. (1994) entamoeba histolytica
anti-neutrophil cytoplasmic 
antibody formation in patients 
with Entamoeba histolytica 
infection  
2.3.5. drugS  
Many drugs have been suspected and even proven to cause autoimmune diseases, 
among these vasculitides such as wG. In a review of the published cases of drug-
induced vasculitis with cutaneous and/or systemic manifestations, ten Holder et al. 
(2002) found propylthiouracil, hydralazine, colony-stimulating factors, allopurinol, 
cefaclor, minocycline, D-penicillamine, phenytoin, isotretinoin  and methotrexate 
to be the drugs most frequently associated with vasculitis. In most cases, vasculitis 
resolved after discontinuing the drug. Severe cases requiring aggressive treatment 
also occurred. There was an overall 10% death rate. 
Bonaci-Nikolic et al. (2005) compared 56 idiopathic ANCA vasculitides and 
16 antithyroid drug-induced ANCA vasculitides. Patients with antithyroid drug-
induced autoimmune diseases were more often female and considerably younger 
than patients with idiopathic vasculitides. Moreover, they presented with less 
constitutional, pulmonary, central nervous system (CNS) and renal symptoms, 
{ {
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but with more skin manifestations. Their diseases also had a more benign course. 
Dolman et al. (1993) and Kitahara et al. (1997) reported similar results. 
2.4. diAgNoStiC ANd CLASSifiCAtioN CritEriA
when Heinz Klinger (1931) originally presented wG, he thought it was a special 
form of polyarteritis nodosa (PAN). Friedrich wegener considered wG to be a 
disease of its own, and he described a classical symptom triad, from a series of 
three obductions (wegener 1936). 
For long, this symptom triad formed the diagnostic criteria of wG. Along with the 
ACR classification criteria for vasculitides in 1990 (Leavitt et al. 1990; Table 3) and 
the criteria of the Chapel Hill Consensus Conference (CHCC) in 1994 (Jennette et al. 
1994; Table 4), a consensus concerning the classification criteria of wG was reached. 
Although these criteria were meant to be classification criteria for vasculitides, they 
have also widely been used for diagnostic purposes. The need for diagnostic criteria 
for wG has long been recognized. In 2000, Sorensen et al. proposed their diagnostic 
criteria (Table 5) largely based on CHCC criteria and complemented with surrogate 
criteria for the frequently missing biopsy results.  The Sorensen criteria have been 
criticized for ruling out patients with eosinophilia (Lane et al. 2002). watts et al. 
(2007) developed a new algorithm for classification of ANCA vasculitides in 2006 
(Table 6). This was validated by Liu et al. (2008) in a large cohort of Chinese 
vasculitis patients and found to be a useful method. 
2.5. trEAtMENt
2.5.1. gLuCoCortiCoidS 
Glucocorticoids (GCs) were the first agents used to treat wG. In many instances, 
their effect was positive and their use prolonged survival time moderately, from a 
median of 5 months to 12.5 months (Hollander et al. 1967). Their effect was poor in 
wG with major organ (particularly the kidney) involvement (Hollander et al. 1967, 
Hoffman 1993, Langford et al. 2001). GC monotherapy can alleviate the disease 
process, but it cannot keep the disease from progressing, nor can it produce a 
sustained remission (Hoffman 1993). The use of GCs brings along well-known side-
effects; they reduce glucose tolerance and increase the risk of diabetes, as well as 
the risk of hypertension, gastrointestinal haemorrhage, obesity and increased ocular 
tension. Prolonged use also causes adrenal suppression and risk of osteoporosis. 
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2.5.2. CyCLophoSphAMidE ANd gLuCoCortiCoidS
A major improvement in the treatment of wG took place when Fauci and wolff 
(1973) developed a treatment combining daily cyclophosphamide (CyC) and GC. The 
standard regimen comprised oral CyC 2 mg/kg/day and prednisolone 1 mg/kg/day. 
Prednisolone dose was tapered slowly after one month to a maintenance dose by 3-4 
months, and the drug was discontinued by 6-12 months. CyC was used one year past 
remission, thereafter being tapered and discontinued (Fauci et al. 1973). Increased 
doses of CyC (3-4 mg/kg/day for a few days) (Fauci et al. 1983) and prednisone (higher 
dose than 1 mg/kg/day) could also be used with critically and fulminantly ill patients.
Combination treatment with CyC and GCs induces remission in about 90% 
of patients (de Groot et al. 2009), and this regimen has prolonged the survival 
of wG patients considerably, from a median of 5 months to as long as 21 years 
(Reinhold-Keller et al. 2000). Several problems occur, especially drug toxicity and 
frequent relapses.
The toxicity of CyC has been a great concern in treating wG. The bone marrow 
toxicity of CyC often compels a reduced dosage, and CyC-induced leukopenia 
renders the patient susceptible to life-threatening bacterial infections and induction 
of immunosuppression to opportunistic infections, e.g. Pneumocystis jiroveci 
pneumonia (Khellaf et al. 2009). CyC’s toxicity to germinal cells bears a risk of 
infertility. There is also a increased risk of malignancies, especially bladder cancer. 
In a study by Talar-williams et al. (1996), 50% of the 145 wG patients receiving CyC 
had non-glomerular haematuria. Seven patients (5%) developed bladder cancer. All 
but one had received a cumulative CyC dose of more than 100 g and the duration 
of CyC therapy had exceeded 2.7 years. Reinhold-Keller et al. (2000) noted that 
the amount of adverse effects (CyC-induced cystitis and myelodysplastic syndrome) 
increased with cumulative CyC doses exceeding 100 g. Knight et al.(2004) observed 
an increasing risk of bladder cancer with increasing total doses of CyC. Faurschou 
et al. (2008) reported significantly increased incidences of acute myeloid leukaemia 
with cumulative CyC dose exceeding 36 g. Because the risk of adverse effects 
mount with increasing cumulative total doses of CyC, regimens with the aim of 
decreasing the total doses have been developed. A few studies have proved that 
treatment with high-dose intravenous CyC pulses reduces the total dose of CyC and 
is fairly efficacious in inducing remission; however, with higher rates of relapses 
occur(Hoffman et al. 1990, Guillevin et al. 1997). de Groot et al. (2009) found in 
their recent study that the pulse CyC regimen induced remission of ANCA-associated 
vasculitis as well as the daily oral regimen at a reduced cumulative CyC dose and 
caused fewer cases of leukopenia. 
whether treated with oral or intravenous CyC, the relapse rate is high. According 
to several studies, about 50% of the wG patients treated with a combination of 
CyC plus GC who had reached remission experienced one or more disease relapses 
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(Tervaert et al. 1990, Hoffman et al. 1992) after a medium of 27 months (westman 
et al. 1998). Reinhold-Keller et al. (2000) found that the relapse rate increased with 
time: 38% for ≤5 years vs. 71% for >5 years. 
2.5.3. MEthotrExAtE ANd gLuCoCortiCoidS
Methotrexate (MTX) is also capable of inducing remission in active wG. It was 
found to be as effective as CyC in remission induction. About 90% of patients 
reached remission with both CyC and MTX by 6 months.  Delayed remission was 
common in patients with more extensive disease or pulmonary involvement (de 
Groot et al. 2005). MTX has been used in patients with active but not life-threatening 
disease (Sneller et al. 1995, Langford et al. 1997). when inducing remission, MTX is 
given at 20-25 mg/week and continued 1-2 years past remission, then tapered and 
discontinued. Prednisolone is used in combination with MTX similarly as with CyC.
MTX treatment, like CyC treatment, is complicated by a susceptibility to 
Pneumocystis jiroveci pneumonia. Liver toxicity, leukopenia, stomatitis and 
pneumonitis also occur. To lessen these toxicities, antibiotic prophylaxis against 
Pneumocystis and administration of folic acid have been recommended (Morgan 
et al. 1994). 
2.5.4. CyCLophoSphAMidE for iNduCtioN ANd MEthotrExAtE for rEMiS-
SioN MAiNtENANCE
Due to considerably high toxicity during CyC treatment, a shorter course with CyC 
has been proposed. In this regimen, the patient is treated with CyC 2 mg/kg/day 
along with prednisone until remission, which is achieved in a medium of 3 months. 
CyC is then changed to MTX 20-25 mg/week. This kind of therapy was found to 
be a good alternative regimen with less toxicity than the standard CyC regimen (de 
Groot et al. 1996, Langford et al. 1999). Up to 30-50% of the patients on remission 
maintenance medication with low-dose MTX experience a relapse after a median 
of 15-19 months. The relapse rate of the patients on remission maintenance with 
MTX does not differ significantly from those on CyC (Reinhold-Keller et al. 2002, 
Langford et al. 2003).
2.5.5 othEr CytotoxiC ANd iMMuNoSupprESSivE AgENtS  
CyC and MTX seem to be the two most powerful drugs to induce remission in wG. 
In some instances, their use is not feasible. In cases of previous CyC-induced bladder 
injury, lymphoproliferative disease or bladder cancer, CyC is not recommended. 
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Liver disease, severe renal insufficiency and severe pulmonary impairment preclude 
the use of MTX. In case of contraindications, alternative drugs must be considered. 
Azathioprine (AZA) does not induce remission successfully, but it can be used 
instead of MTX to sustain CyC-induced remission (Fauci et al. 1983). Relapse rates 
during maintenance therapy on AZA (58% during 18 months) are similar to those 
on CyC, but AZA is considered a safer medication (Jayne et al. 2003, Slot et al. 
2004). In more recent studies, relapse rates with AZA maintenance therapy, have 
been 15.5-17.8% at 18 months and 50-52% at 32 months (Pagnoux et al.2008).  
Leflunomide at a dose of 30 mg/day is at least as effective as MTX in maintaining 
remission, but it has more adverse effects such as hypertension, neuropathies and 
leukopenia (Metzler et al. 2007).  
Mycophenolate mofetil (MMF) can be used for maintenance of remission in wG 
(Nowack et al. 1999). while it was well tolerated, it was associated with a relapse 
rate of 43% at a median of 10 months after remission (Langford et al. 2004). Silva 
et al. (2010) found MMF to be a good alternative for induction and maintenance 
of remission in microscopic polyangiitis.
2.5.6. BioLogiCAL AgENtS
Interferon gamma (IFNγ), interleukins and tumour necrosis factor alpha (TNFα) 
have been demonstrated to be important factors in the disease process of wG, in 
particular in granuloma formation (Komocsi et al. 2002, Lamprecht et al. 2002a). 
Therefore, therapies targeted against cytokines are under extensive investigation 
and development.  
Biological agents have been developed and adapted into clinical use since the 
1990s. They have not had a role in the first-line treatment for wG, but rather 
as a rescue therapy in refractory cases. A few reports of successful treatment of 
adult patients with infliximab exist (Lamprecht et al. 2002b&c, Rozin et al. 2003, 
Hermann et al. 2006, Svozilkova et al. 2006, Fujikawa et al. 2008). In paediatric 
cases, the therapy has not been promising. Etanercept has not proven efficacious 
in wG (wilkinson et al. 2006, Ramos-Casals et al. 2008). Interleukin-1-antagonist 
(anakinra) and anti-CD-20-antibody (rituximab) have shown promise, especially 
in the treatment of wG with renal involvement (Borgmann et al. 2003, Jayne et 
al. 2009). Rituximab has proven effective in preponderantly vasculitic wG, with 
few adverse effects (Hinze et al.2008, Moosig et al. 2008, Sanchez-Cano et al. 
2008, wong 2008). In two recent studies, rituximab and CyC were compared in 
the treatment of AAV; the drugs were equally efficacious and had equal amounts 
of adverse effects (Jones et al. 2010, Stone et al. 2010).
Biological therapy is shadowed by frequent side-effects. Serious infections (e.g. 
re-activation of tuberculosis) on anti-TNF therapies are of the greatest concern 
(Bruns et al. 2009).  
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Although occasional promising results have been presented, much consideration 
is still required in the use of biological agents to treat wG (Langford 2008). with 
no risk of infertility (in contrast to CyC), they can be a good alternative for patients 
in their fertile years (Ntatsaki et al. 2011).
2.5.7. othEr thErApiES
Because of the alleged role of Staphylococcus aureus in the aetiopathogenesis 
of wG, long-term antibiotic treatment has been used in a limited form of the 
disease. Trimethoprim-sulphamethoxazole treatment has been found to be useful 
in preventing relapses (DeRemee et al. 1985, Stegeman et al. 1994 and 1996, Zycinska 
et al. 2008). Mupirocin ointment has been used to reduce nasal carriage of S. aureus 
(Crossley et al. 2009). 
Intravenous immunoglobulin infusions have been used occasionally to treat wG. 
Some good results have been reported, but others have been controversial. Generally, 
the therapy is well tolerated (Richter et al 1995, Jayne et al. 1996, Lockwood 1996).
Plasma exchange is indicated for severe renal vasculitis, leading to a renal 
recovery rate of up to 80%. Plasma exchange has been used as an adjuvant rescue 
therapy with simultaneously continuing CyC and prednisolone medication (Jayne 
2009).
2.6. CourSE of thE diSEASE
Evidence indicates that wG with granulomatous predominance runs a more 
prolonged but benign course than wG with vasculitic predominance (Mahr et al. 
2001, Mukhtyar et al. 2008). 
2.6.1 progNoSiS
Long after the introduction of wG in the 1930s, its prognosis remained quite sinister, 
although occasional spontaneous recoveries occurred (Thomas et al. 2007). with 
no efficient treatment available, the mean life expectancy after diagnosis was about 
5 months in the 1950s, with a one-year mortality of 80% (walton 1958).  The 
use of GCs improved the prognosis slightly, approximately doubling the survival 
time (Hollander et al. 1967, Hoffman 1993, Langford 2001). The development 
of combination treatments with cytotoxic drugs (in particular CyC) and GCs 
revolutionized the treatment of wG, improving the prognosis markedly (Fauci et 
al. 1983).
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Nowadays, wG patients live even decades after diagnosis. However, ANCA-
associated vasculitis still means excess mortality compared with the general 
population. In a recent study, patients with ANCA-vasculitides in 1995-2002 had 
a standardized mortality ratio (SMR) of 2.6 (Flossmann et al. 2011). 
Treatment can be associated with adverse events, such as leukopenia, which 
leads to susceptibility to severe infections. Treating young patients with cytotoxic 
agents is associated with  a risk of infertility.   In addition a risk of long-term adverse 
effects, such as malignancies, presents with prolonged use of CyC at high cumulative 
doses. Long-term treatment with GCs increases the risk for diabetes, elevated blood 
pressure, osteoporosis and cataract (Knight et al. 2004, Faurschou et al. 2008).
Kidneys are involved in ca. 70% of wG patients at the time of diagnosis (Cisternas 
et al. 2005, Gottenberg et al. 2007), and the proportion rises to 85% in the course 
of the disease. Approximately 20% of wG patients develop renal failure (Aasarod et 
al. 2000, Cisternas et al. 2005, Geetha et al. 2007). Left untreated, renal failure is 
inevitably fatal. The development of methods of dialysis and renal transplantation 
has dramatically improved the outcome of patients with end-state renal disease 
(ESRD). These patients can survive for long periods on dialysis, but their lives are 
very restricted. Only after successful kidney transplantation can they lead fairly 
normal lives (Geetha et al. 2007).  
If untreated, patients with wG would probably succumb to organ failure due 
to vasculitis (renal insufficiency, pulmonary haemorrhage, respiratory failure, 
etc.) with effective treatment regimens, the inflammatory process of wG as the 
immediate cause of death has become more uncommon. In three recent studies with 
mean follow-up times of 1.9-8.8 years, vasculitis itself was responsible for 24-50% 
and infections for 33-48% of the deaths of wG patients (Mahr et al. 2001, Bligny 
et al. 2004, Flores-Suaréz et al. 2007).
3.6.2 progNoStiC fACtorS
Mukhtyar et al. (2008) found in their review of 61 articles different survival rates 
between genders. Men had a somewhat greater mortality risk. Mortality risk ratio 
(MRR) was 4.0 for men and 3.4 for women. In various studies, a relationship 
between increasing age at diagnosis and decreasing survival has been reported. 
Kidney involvement, particularly elevated serum creatinine value at an early stage 
of the disease,  has been associated with worse prognosis, as has lung involvement, 
elevated ESR values (Mahr et al. 2001) and reduced blood haemoglobin (Bligny et 
al. 2004). By contrast, ENT involvement has predicted a better prognosis (Mahr et 
al. 2001, Koldingsnes et al. 2002, Bligny et al. 2004, Pavone et al. 2006, Mukhtyar 
et al. 2008, Mohammad et al. 2009). 
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3. AIMS OF THE STUDy
1. To investigate the incidence of wG and its changes in Finland in 1981-2000. 
2. To evaluate clinical presentation, diagnostic delay and factors affecting the 
delay in patients diagnosed with wG in Finland in 1981-2000.
3. To determine the occurrence of dialysis dependent renal disease and factors 
affecting the risk of dialysis in patients diagnosed with wG in Finland in 
1981-2000.
4. To assess mortality and associated factors in patients diagnosed with wG 
in Finland in 1981-2000.
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4. PATIENTS AND METHODS
4.1. pAtiENtS
Hospital discharge registers (National Research and Development Centre for 
welfare and Health, STAKES) were screened for all patients with a discharge 
diagnosis of wG during 1981-2000 (1981-1986 based on ICD8, 1987-1995 on ICD9, 
1996-2000 on ICD10). These patients were allegedly wG patients, but the reason 
for their hospital admission was not necessarily connected to wG. The register data 
showed in which hospital the patient was treated and for how long. All available 
patient files were then reviewed. To estimate the risk of dialysis-dependent renal 
insufficiency and kidney transplant, this information was complemented with files 
provided by the Finnish Registry for Kidney Diseases. Statistics Finland provided 
the dates and causes of death of the patients. From the registry files, data were 
collected up to year 2005 in order to have a sufficiently long follow-up for 5-year 
survival statistics.  
Patients treated only in health centres were not included in this study (n=45) 
because their data would not have been comparable with the data for the rest of 
the patients.  
In all, 661 patients treated in Finnish hospitals in 1981-2000 had wG as one 
of the discharge diagnoses in the hospital discharge registers. At least some data 
were available on 585 patients in  patient files. After the review of patient files, the 
diagnosis of wG was confirmed for 513 patients. In 492 cases, the diagnosis was 
set in 1981-2000 (Figure 2). 
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Figure 2. Flowchart  of data retrieval.
661 patients treated in 1981-
2000 with a discharge diagno-
sis of WG
45 patients treated only in 
health centres
616 patients treated in hospi-
tals of specialized health care
Data not available for 31 pa-
tients
Data available for 585 patients
72 patients with erroneous 
code  or inadequate data
513 WG patients with verified 
diagnosis treated in hospitals 
of specialized care care
21 patients diagnosed before 
1981  
492 patients diagnosed in 
1981-2000
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4.2. EthiCAL ASpECtS 
The Ethics Committees of Helsinki University Central Hospital and Kajaani Central 
Hospital and the National Advisory Board on Health Care Ethics approved the 
study protocol.
4.3. MEthodS
From patient files, data were collected on: 
1. clinical features (consistent with wG, see page 19) at presentation, at diagnosis 
and cumulative features thereafter 
2. laboratory results (annually): 
– blood test for haemoglobin, leukocyte count, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), serum creatinine and anti-neutrophil 
cytoplasmic antibodies (ANCA†),
– urine tests for haematuria and proteinuria 
3. histology for diagnosis of wG
4. medical treatment for wG
5. all significant comorbidities 
6. malignancies
In the process of data collection, the following definitions were applied:
 Symptom onset: The time the first wG-related symptom appeared. Persistence 
of wG-related symptoms subsequently led to the suspicion of wG. 
 Date of diagnosis: The point at which the treating physician suggested wG 
in the patient’s files was interpreted as the time of diagnosis. If not otherwise 
defined, the day CyC therapy was started was regarded as the day of diagnosis. 
The diagnosis of wG was ascertained, based on cumulative clinical features 
consistent with the presentation of wG (see page 19): 
– appropriate ENT (ear, nose, throat), pulmonary and renal symptoms and signs 
– indications of generalized inflammatory disease 
 *malaise, fatigue, fever
– relevant laboratory findings 
 *anaemia, high ESR, high level of CRP, positive ANCA† test
 *proteinuria, haematuria, urine sediment consistent with glomerulonephritis, 
elevated serum creatinine values
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– histology consistent with wG
†ANCA depicted as positive or negative (see section 5.5)
 
Based on the cumulative information available, the extent to which a patient’s 
characteristics agreed with ACR classification criteria, Sorensen diagnostic criteria 
and watts diagnostic criteria was determined (Leavitt et al. 1990, Sorensen et al. 
2000, watts et al. 2007; Tables 3, 5, 6).
 The study period covered hospital admissions from 1 January 1981 to 31 
December 2000. A patient was included in the study only when his/her diagnosis 
of wG was made within the 20-year period of 1981-2000. This period was divided 
into either two 10-year periods (1981-1990 and 1991-2000) or four 5-year periods 
(1981-1985, 1986-1990, 1991-1995 and 1996-2000). 
4.4. StAtiStiCAL ANALySES
The results were expressed as mean or median, standard deviation (SD) or 
interquartile range (IQR), and 95% confidence intervals (95% CIs). The statistical 
significance between groups was evaluated with analysis of variance (ANOVA), 
Kruskall-wallis test, Mann-whitney U-test or χ2 test with a Monte Carlo p-value 
when appropriate. Statistical significance for hypotheses of linearity was evaluated 
by using ANOVA, Jonckheere–Terpstra test, Cochran–Armitage test, χ2 test and 
median regression analysis (least–absolute-value models).
Time-to-event analysis was based on the product limit estimate (Kaplan-Meier) 
of the cumulative “survival” function. The prognostic factors to predict the duration 
of progression-free “survival” and to estimate the age- and sex-adjusted risk for 
mortality were analysed using multivariate proportional hazard regression models 
(Cox’s regression models). The proportional hazard assumption was tested for all 
variables in the selected models graphically and formally. The ratio between observed 
and expected numbers, the standardized mortality ratio (SMR), was calculated using 
subject-year methods with 95% CIs, assuming a Poisson distribution. Probabilities 
of survival in an age- and sex-matched sample of the general population were 
calculated from data from the Official Statistics of Finland. 
Patients and the population at risk were stratified by gender and age (5-14, 15-
24, 25-34, 35-44, 45-54, 55-64, 65-74 and 75+), and crude and adjusted incidence 
rates with 95% CIs were calculated. Standardized estimates of wG incidence rate 
ratios (IRRs) were calculated by using Poisson or negative binomial regression 
models when appropriate.
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5. RESULTS AND DISCUSSION
5.1 pAtiENtS
Altogether 492 patients, 243 men and 249 women, were diagnosed with wG at a 
mean age of 53.7 (SD 18,1) years (median 56 years). At diagnosis, patients of the 
last 5-year period were some 9 years older than those of the first period. During 
the first three 5-year periods, female patients slightly outnumbered male patients, 
but in 1996-2000, the situation was reversed (Table 10). 
 The results are in line with other studies from the Nordic countries. In a 
Norwegian epidemiological study in 1992-1996, a clear majority (65%) of PSV 
patients were female; wG patients were not singled out (Haugeberg et al. 1998). 
In another Norwegian study of wG patients in 1984-1998, men predominated 
(62%) (Koldingsnes et al. 2000). In Sweden, 64% of wG patients in 1975- 2001 
were male (Knight et al. 2006).  
5.2 iNCidENCE (i)
The crude incidence in this study was 1.9 per million per year in 1981-1985, and 
this rose to 9.3 per million per year in 1996-2000. The corresponding annual 
age-adjusted incidence rate ratio (IRR) was 5.2 per million for men and 4.0 per 
million for women. The incidence was somewhat higher in women in the first three 
5-year periods, but in 1996-2000 there was a slight male predominance. Also age 
at diagnosis increased from 46 years in the first 5-year period (1981-1985) to 55 
years in the last 5-year period (1996-2000) (p between periods=0.014). Incidence 
peaked in the age group 65-74 years among both sexes (Table 11).  
A 4.5-fold increase occurred in the incidence of wG during the study period. 
This finding is fairly consistent with other results in recent years, especially from 
Nordic countries. In Sweden and Norway, the incidence of wG increased 2.3-fold 
in 15 years (Koldingsnes et al. 2000, Knight et al. 2006). In the UK, a small rise in 
incidence was observed in 10 years (watts et al. 2000). Some other studies have, 
however, failed to show any increase in incidence (watts et al. 2001, Reinhold-
Keller et al. 2005). 
Discussions and speculations have centred around whether the increased 
incidence of wG is due to improved recognition of the disease or better diagnostic 
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methods and whether the incidence in fact is trully rising (Carruthers DM et al. 
1996). All of these factors may contribute to the results.    
Tests for ANCA antibodies became available in the mid-1980s. ANCA tests 
were first performed in Finland in 1985. The tests rapidly became popular in the 
clinics, facilitating recognition and diagnosis of wG. In this study, a clear increase 
occurred in the incidence of wG from 1985 onwards. The increase coincides well 
with increasing use of ANCA tests (Figures 3 and 4). Results show, however, that 
although virtually all new wG patients were tested for ANCA in 1991-1995 as well 
as in 1996-2000, the incidence increased between these periods (Tables 10 and 
11). This implies that testing for ANCA is not the sole reason for the increasing 
incidence, athough it is an important one. It can also be assumed that ANCA tests 
had improved in accuracy and sensitivity in 1985-2000, making comparison of 
test results somewhat unreliable. There could also have been a genuine increase 
in the incidence of wG.   
The introduction of the ACR criteria in 1990 may also have facilitated diagnosis 
of wG and made it more accurate. On the other hand, our results reveal that patients 
diagnosed in the 1980s were more often ACR-positive than those diagnosed in the 
1990s (Table 10). 
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Figure 3. annual incidence of Wegener’s granulomatosis in Finland in 1981-2000.
 
Figure 4. anca tests performed on Wegener’s granulomatosis patients in the year 
of diagnosis in Finland in 1981-2000.
 
The development of other diagnostic methods likely had an impact on diagnosis 
of wG. Novel imaging techniques, such as computed tomography (CT) and 
magnetic resonance imagining (MRI), may reveal otherwise inaccessible disease 
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manifestations, e.g. in the central nervous system. Improved surgical and mini-
invasive methods and endoscopic equipment have provided better tissue samples. 
The incidence of wG might actually be on the rise, too. This is suggested by 
the parallel results of independent studies (Koldingsnes et al. 2000, Knight et al. 
2006), including the present study. The question then becomes: If the incidence 
is truly increasing, what is the cause? Hypotheses include elevated amounts of 
inhaled unhealthy substances, heretofore unknown infectious agents and changed 
microbiological environment that alters immunological reactions (de Lind van 
wijngaarden et al. 2008). 
Studies reported mean ages of 40- 50 years at onset of wG in the 1950s to 1980s 
(Littlejohn et al. 1985, Hunder et al. 1990, Kelley et al. 1993). By contrast, studies in 
the 2000s have demonstrated median ages of about 60 years at diagnosis (Reinhold-
Keller et al. 2005, Knight et al. 2006). However, several studies have failed to report 
increasing ages at diagnosis (Koldingsnes et al. 2000, Reinhold-Keller et al. 2005, 
Knight et al. 2006). The results of the present study show uniform increasing ages 
at diagnosis throughout the two decades of the survey (Table 10). Previous studies 
have shown a peak in incidence around the age of 70, consistent with our findings 
(Koldingsnes et al. 2000, watts et al. 2000, Lane et al. 2005). 
Some unknown factor seems to postpone wG to a more advanced age nowadays. 
Better hygiene and more rigorous control of infections, diminishing the strain on 
immunologic defence, are potential contributing factors. However, the increasing 
incidence of wG contradicts this possibility.   
5.3. CLiNiCAL prESENtAtioN (i, ii)
Data on involvement of different organ groups in various stages of disease were 
available for 489 patients. An average of 1.8 organ groups were simultaneously 
involved at the beginning of wG-related symptoms. The ENT (ear, nose and throat) 
system was affected most frequently, in 45% of patients. Lungs were involved in 
36% of cases, and 36% of patients presented with constitutional symptoms and signs 
(fever, malaise, fatigue, other aberrations of general well-being and inflammation-
related laboratory findings )(Table 12). 
within the first six months of onset of wG symptoms, ENT was the still the 
most frequently involved organ group (63% of cases). Pulmonary involvement was 
present in 59% of cases. Constitutional symptoms were present in 60% of patients. 
Kidneys were involved in 40%, musculoskeletal system in 39%, eyes in 17% and skin 
in 17% of cases. In 1981-1985, 49% of patients had constitutional symptoms during 
the first six months of their symptomatic period, but in 1996-2000 as many as 66%. 
This change was statistically significant, but not after multiplicity adjustment. No 
significant change occurred in initial ELK score (Figure 5, Table 13).
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Proportions of involvement of all major organ groups grew over the course of 
the disease. Involvement of kidneys and eyes increased 6-fold, other organ groups 
less, albeit markedly (Table 12).  
The agreement of patient data with the criteria of ACR (Leavitt et al. 1990), 
Sorensen (Sorensen et a. 2000) and watts (watts et al. 2007) was tested with 
respect to the four 5-year periods. The best agreement was with the criteria of watts 
(90%) and ACR (83%) (Table 14). Only the agreement with the watts et al. criteria 
differed significantly between the 5-year periods (p<0.001).     
Presenting features at disease onset remained quite similar during the study. Only 
constitutional symptoms became somewhat more common with time (Table 13). 
wG has a clear tendency to develop from its restricted form to a more generalized 
disease. This is shown by numerous preceding studies (Table 8), and also by the 
present study (Table 12).    
Consistent with a Norwegian study (Koldigsnes et al. 2000), our study 
demonstrates a stable clinical picture in the initial stages of wG over years (Table 
13). Although the disease is recognized increasingly rapidly, the disease has remained 
uniformly aggressive. It can be hypothesized that perhaps the same factors that 
contribute to the increased incidence (e.g. infections, inhaled substances, pollution, 
silica) alter the very character of wG.
Table 12. organ involvement (%) in different phases of the disease in 489 patients.
phase of disease
at presentation First 6 months at diagnosis at any time
kidney 11 40 60 64
ent 45 63 75 82
lung 36 59 77 85
Musculoskeletal 22 39 48 57
eye 5 17 28 37
constitutional 36 60 83 87
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Table 14. agreement of the patient data with classification criteria of Wegener’s granulomatosis.  
5-year period
1981-1985 1986-1990 1991-1995 1996-2000 all
n=43 n=83 n=141 n=225 n=492
acR classification*
0 criteria present 2 (5) 1 (1) 3 (2) 6 (3) 12 (2)
1 criteria present 1 (2) 11 (13) 23 (16) 35 (16) 70 (14)
2 criteria present 6 (14) 21 (25) 38(27) 80 (36) 145 (29)
3 criteria present 20 (47) 29 (35) 57 (40) 84 (37) 190 (39)
4 criteria present 14 (33) 21 (25) 20 (14) 20 (9) 75 (15)
≥2 criteria present
(=acR+)
40 (93) 71 (86) 115 (82) 184 (82) 410 (83)
sorensen criteria** 17 (40) 32 (39) 48 (34) 84 (37) 181 (37)
Watts criteria*** 26 (61) 78 (94) 128 (91) 210 (93) 442 (90)
* leavitt et al. 1990 
** sorensen et al. 2000 
*** Watts et al. 2007
5.4. diAgNoStiC dELAy (ii)
Diagnostic delay was calculated for every patient for whom the data on the initial 
stages of the disease were available (N=489). Diagnostic delay was defined as a 
median period of time starting the day the first symptoms and signs consistent 
with wG appeared and ending on the day of diagnosis. Moreover, that at least one 
wG-related symptom had to be present constantly until the diagnosis was set. we 
also analysed factors with an impact on diagnostic delay.
The diagnostic delay shortened from a median of 17 months in 1981-1985 to 4 
months in 1996-2000. The change in diagnostic delay was most prominent between 
the first and second 5-year periods (Table 10).
Gender and age had no significant effect on diagnostic delay, but patients with 
initial lung involvement and constitutional symptoms had a significantly shorter 
delay (Table 15), as did patients with an initially high ESR. High ELK score also 
associated with a shorter diagnostic delay. Patients with ELK scores of 2 and 3 had 
a median diagnostic delay of 3 (IQR 1 , 5.5) and 2 (IQR 1 , 6) months, respectively. 
The corresponding median delay values were 17 (IQR 12 , 35) and 11.5 (IQR 4 , 46) 
months for patients with ELK scores of 0 and 1. This trend was significant (p<0.001). 
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Table 15. Median regression analysis for the effect of gender, age and organ involvement on diagnostic delay.
variable β (95%ci†) p-value
Male gender -1 (-3 to 1) 0.21
age 0 (0 to 0) 0.99
kidney involvement -1 (-2 to 0) 0.16
ent involvement -1 (-2 to 0) 0.29
lung involvement -4 (-7 to -1) 0.005
constitutional symptoms -9 (-13 to -5) <0.001
constant 17
Abbreviations: ent=ear, nose and throat;  constitutional symptoms=symptoms and signs of 
generalized inflammatory disease including fever, malaise, fatigue and other aberrations of general 
well-being, or abnormal laboratory findings related to general inflammation such as anaemia, 
elevated values of erythrocyte sedimentation rate and c-reactive protein. 
† Bootstrap standard errors.
Reasons for the decrease in diagnostic delay were probably mostly the same as for 
the increase in incidence: increased awareness of the disease, availability of ANCA 
tests and other improved diagnostic facilities. Despite these, however, the disease 
did not become milder over time, but instead presented with more constitutional 
symptoms, which supposedly led to prompt investigations and diagnosis (Table 13). 
In addition, a high ELK score is an indicator of a widespread disease, and a patient 
with a widespread disease is evidently investigated promptly. Thus, patients with 
higher ELK scores had considerably shorter median diagnostic delay than patients 
with less advanced disease.  
The results of diagnostic delay are in line with the median value of 4.5 months in 
a previous study (Lane et al. 2005). In a recent Swedish study of 95 wG and MPA 
patients, no significant difference in diagnostic delay was found between the periods 
1978-1996 and 1997-2005. A minor tendency did, however, emerge; delays were 
186 days (about 6 months) and 121 days (about 4 months), respectively (Eriksson 
et al. 2009). These results are quite similar to ours.  
5.5. roLE oN ANCA ANtiBody tEStS iN thE diAgNoSiS
ANCA tests were introduced to the diagnostic repertoire in 1985 and PR3-ANCA 
in 1986 in Finland (Figure 4). Only 30 of the patients of this study were diagnosed 
with wG before 1985 (“pre-ANCA era”). Of them, 18 were tested for ANCA later in 
the course of their diseases; 11 were ANCA-positive (Table 10).  Of the 423 patients 
examined for ANCA antibodies in the year of diagnosis, 399 (94%) were ANCA-
positive. Of the 24 patients negative for ANCA during the first year, five became 
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ANCA-positive later. The diagnostic delay decreased the most after the introduction 
of ANCA tests in 1985 and PR3-ANCA in 1986. 
The methods for detecting ANCA antibodies were heterogeneous, particularly 
in the 1980s.
Often no information of ANCA subclasses could be found in hospital records. 
Therefore, patients of this study were depicted merely as ANCA-positive or -negative. 
Of the 411 ANCA-positive patients, 219 were tested and found t be positive for PR3-
ANCA and 28 for MPO-ANCA. ANCA tests in the 1980s and 1990s likely differed 
in sensitivity and specificity, making interpretation of test results unreliable. 
In an epidemiologic study by Koldigsnes et al. (2000) in Norway in 1984-1998, 
only patients fulfilling ACR criteria were included. The annual incidence increased 
more than 2-fold (from 5.2 to 12.0/ million/year), although ANCA testing was 
not used as an inclusion criterion. In a Swedish study by Knight et al. (2006), the 
incidence of wG more than tripled in 1971-2001 (from 3.3 to 11.9/ million/year). 
The increase partly coincided with the introduction of ANCA into routine use, but 
some increase took place even in the pre-ANCA period.   
Performing ANCA tests probably also decreases the number of biopsies taken. 
A biopsy consistent with wG was performed on 76.7% of patients in 1981-1985, in 
contrast to 59.1% in 1996-2000 (p=0.002). A similar trend was evident in a recent 
large study in USA (Abdou et al. 2002).    
5.6. trEAtMENt
The treatment of wG followed similar lines throughout the 20 years. Of all wG 
patients, 75.4% were treated initially with CyC for a known period of time in 1981-
1990 and 78.1% in 1991-2000. In some stage of their illnesses, 86.6% of patients 
were treated with CyC (91.3% vs. 85.0% for the two decades, respectively). Both 
genders were treated equally often with CyC, but in females the medication was 
frequently started later. In 55% of women and 35% of men, CyC was started six or 
more months after the appearance of the first symptoms of wG. The cumulative 
dose of CyC could be calculated for 367 patients. The median cumulative dose 
was smaller in women (32.6 g [IQR 12.4 , 59.7]) than in men (41.6 g [IQR 13.2 , 
77.8]). The total doses of CyC decreased somewhat during the survey; the median 
cumulative total dose was 50.5, 50.1, 41.3 and 23.3 grams per patient during the 
four consecutive 5-year periods (1981-1985, 1986-1990, 1991-1995, 1996-2000).    
Immunosuppressive agents other than CyC (azathioprine, methotrexate, 
cyclosporine, leflunomide, mycophenolate mofetil, podophyllotoxin, vincristine, 
cytarabine) were seldom used. Only 4.3% of all patients were treated with them 
and never received CyC.
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GC treatment was used in a vast majority of the patients; 87.3% of patients in 
1981-1990 and 93.7% in 1991-2000 were treated with GCs at least temporarily. Five 
patients were treated with a TNFα blocking agent (infliximab) after unsuccessful 
treatment with CyC. The use of a long-term antibiotic medication (mostly 
sulphatrimethoprim) increased from 1981-1990 to 1996-2000 (16.7% vs. 28.2%, 
respectively).
No real progress in the treatment of wG took place in the 1980s and the 
1990s. Treatment was mostly based on Fauci’s scheme (Fauci et al. 1973). Some 
modifications of the scheme were developed to reduce the total dose, and hence, 
the adverse effects of CyC (Hoffman et al. 1990, Guillevin et al. 1997). Reducing 
total CyC doses was also an aim in Finland in 1981-2000 (see above).  
5.7. outCoME
5.7.1. KidNEy SurvivAL (iii)
5.7.1.1.  Renal insufficiency
At the year of diagnosis, 150 patients (30.1% of all patients) had impending renal 
insufficiency, i.e. serum creatinine values of 160 mmol/l or more. Of them, 47 (9.6% 
of all patients) had serum creatinine values ≥500 µmol/l.
5.7.1.2.  Dialysis
Eighty-four patients (34 women and 50 men; 17% of all 492 wG patients) needed 
dialysis before 8 October 2005. In this patient group, the median time from the 
the first wG-related symptoms to dialysis was 9 months (IQR 1 , 63). The product-
limit estimate of the rate of developing kidney involvement leading to transient or 
permanent dialysis for renal insufficiency was 14.6% (95% CI: 11.6 to 18.2) at 5 
years and 29.6% (95% CI: 21.5 to 40.0) at 20 years after onset of wG symptoms. 
The 5-year and 20-year rates were 11.7% (95% CI: 8.0 to 16.8) and 31.3% (95% CI: 
18.5 to 49.9), respectively, in women and 17.5% (95% CI: 13.1 to 23.2) and 27.8% 
(95% CI: 19.9 to 38.1) in men; the age-adjusted hazard ratio was 1.53 (95% CI 0.98 
to 2.37) (p=0.059).
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Sixty-three percent of patients needing dialysis were male. The age of dialysed 
patients at diagnosis did not differ significantly from that of non-dialysed. Dialysed 
patients significantly more often had kidney involvement during the first six months 
after onset of wG symptoms (p=0.009) and elevated serum creatinine values at 
diagnosis (p<0.001) than non-dialysed patients.
Alhough 150 patients (30%) had elevated serum creatinine values (≥160 µmol/l) 
in the year of their wG diagnosis, only 61 of them received dialysis. Of the remaining 
89 (non-dialysed) patients, 47 died during the survey. Thus, 42 of those 150 patients 
(28%) with impending renal insufficiency survived and were never dialysed.    
Even 12 of the 47 patients with serum creatinine values ≥500 µmol/l were never 
dialysed. Nine of these patients died before the end of the survey, but three of them 
survived and their renal function recovered (Figure 8). 
In previous studies, the frequency of renal involvement at presentation of wG 
has been reported to be 11-18%, risk of chronic renal insufficiency ~ 40% (Samarkos 
et al. 2005) and  risk for end-stage renal disease ~ 20% in patients with ANCA-
associated vasculitis (Geetha et al. 2007). 
5.7.1.3.  Chronic dialysis 
In 32 of the 84 dialysed patients (38%), the first dialysis became chronic, i.e. it was 
prolonged for three months or more. Of these patients, 18 (56%) were male. Patients 
with chronic dialysis and the rest of the wG patients differed significantly in age at 
diagnosis (mean 46.1 vs. 54.2 years; p= 0.014), but not in the delay from the first wG-
related symptoms until diagnosis (mean 42.1 vs. 27.7 months). They were equally 
often positive for ANCA tests and ACR criteria; their organ system involvement 
during the first six months differed only for renal involvement (p<0.015). The delay 
from the first wG-related symptoms until CyC medication (median 11 vs. 7 months) 
and until GC medication (median 4 vs. 4 months) did not differ significantly.
5.7.1.4.  Risk factors for acute and chronic dialysis
The most significant risk factor for acute and chronic dialysis was elevated serum 
creatinine level at diagnosis of wG. Renal involvement at 6 months was a risk factor 
for acute dialysis, but not for chronic dialysis (Table 16).  
Elevated serum creatinine value and advanced age at disease initiation have been 
shown to be risk factors for acute and chronic dialysis in several studies (Aasarod 
et al. 2000, Koldigsnes et al. 2002, Gottenberg et al. 2007).
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5.7.1.5.  Transplantation 
Nineteen patients (8 women, 11 men; 22.6% of dialysed patients, 3.9% of all patients) 
received a renal transplant. Median time from the first dialysis to transplantation was 
3.1 years (IQR 1.5 , 6.5). The long-term survival of transplanted kidneys was good. 
One patient was transplanted twice because of acute rejection of the first transplant 
and another patient needed dialysis again 5.5 years after his transplantation. 
Similar good results have been published elsewhere (wrenger et al. 1997, Ounissi 
et al. 2009). Patients transplanted for wG-related renal disease have been found 
to do better than those transplanted for other renal diseases (Shen et al. 2010).   
The good results imply that kidney transplantations were prepared and 
conducted with great care. Preparations include treating the disease process 
of wG to remission and finding a suitable donor. This procedure takes a lot of 
time, and patients must spend months and even years on dialysis waiting for the 
transplantation. After transplantation, proper anti-rejection medication is needed; 
this medication probably precludes recurrence of the underlying vasculitis. The 
relapse rate of AAV after kidney transplantation has been reported to be 0.006-0.1 
per patient per year (Geetha et al. 2007) or 12-17.3% (Rostaing et al. 1997, Nachman 
et al. 1999). Unfortunately possible AAV recurrences in the patients of the present 
study are unknown.
5.7.1.6  Renal outcome
Information on the cause of discontinuation of the first dialysis was available for 
75 of the 84 dialysed patients. In 32 (38%) of the dialysed patients, renal function 
recovered. Fifteen patients (18%) received a renal transplant, and 27 patients (32%) 
died during the first dialysis. Active treatment was withdrawn from one patient 
who succumbed shortly thereafter. Eleven patients needed re-dialysis later after 
having temporarily recovered. Altogether 19 patients (3.9% of all 492 wG patients) 
received a kidney transplant. 
One hundred and fifty patients (30% of wG patients) had an elevated serum 
creatinine value (≥160 µmol/l) in the year of diagnosis. Sixty of them plus another 
24 patients were dialysed. Forty-seven patients had a creatinine value as high as 
≥500 µmol/l in the year of diagnosis. yet only 35 of them were ever dialysed. Of 
the 12 non-dialysed patients, 3 were alive at the end of the follow-up (Figure 6). 
Of those 84 patients needing dialysis at some point in their disease, dialysis 
was discontinued for 32, often temporarily, due to recovery of renal function. One 
hundred and seventy-four patients (35%) had at least impending renal insufficiency 
in some phase of their diseases. Of these, 122 patients (70% of patients with renal 
insufficiency) regained their renal function, often temporarily, with wG treatment. 
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These findings are in line with previously published studies (Aasarod et al. 2000, 
Koldingsnes et al. 2002, Jayne 2009). Rarely, patients with serum creatinine as 
high as ≥500 µmol/l may regain renal function. 
All 174 patients in the present study with impending or manifest renal 
insufficiency probably would have had lost kidney function totally and permanently 
without treatment. Even for five of the 32 patients dialysed ≥3 months, kidney 
function recovered with treatment and dialysis could be ceased. Thus, chronic 
dialysis (≥3 months) does not always represent an irreversible and final end-state 
renal disease (ESRD) (Figure 6).  
 Forty-one (48.8%) of all 84 dialyzed wG patients were alive on 8 October 2005; 
16 were alive with a functioning kidney transplant, 14 were on dialysis and 11 had 
their own functioning kidneys and were not on dialysis.   
5.7.2. MALigNANCiES
Eighty-three (18.9%) of the 492 wG patients were diagnosed with 113 malignancies, 
a majority of which were malignancies of the skin (n=42), followed by malignancies 
of the gastrointestinal tract (n=20) and urinary bladder (n=11). Of the 53 patients 
treated with AZA, 10 were diagnosed with cancer; 4 of them were cancers of the skin. 
Because of the small number of cancer patients and the lack of population control 
data on the incidence of malignancies, there was no opportunity to estimate whether 
wG patients had a medication-related enhanced risk of malignant neoplasms. 
However, our results imply that CyC has a role in the aetiology of bladder cancer. 
The vast majority (9/11) of the patients with bladder cancer belong to the group of 
patients receiving the largest total doses of CyC (Figure 7).
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Figure 7. Proportion of patients with urinary bladder cancer accordng to the quartiles of total dose of 
cyclophosphamide (cyc). Quartiles: i =0-12.9 g, ii =13.0-26.7 g, iii =36.8-69.3 g, iv =69.5-124.9 g. n=367
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CyC-treated patients have been reported to have an increased risk of malignancies, 
especially leukaemia and urinary bladder cancer (Faurschou et al. 2008). AZA 
treatment has been found to increase lymphoma risk four-fold (Kandiel et al. 2005).
In a recent Norwegian study, some increase, albeit not significant, was observed in 
the  incidence of various malignancies among 75 patients with systemic autoimmune 
diseases previously treated with intravenous CyC. In that study, even when no 
mesna prophylaxis was given, neither haemorrhagic cystitis nor urinary bladder 
cancer occurred (Goransson et al. 2008). 
5.7.3. MortALity (iv)
Of the 492 patients, 203 (99 men and 104 women) died before the end of June 
2005. wG or another connective tissue disease was the most frequent underlying 
cause of death (39%)*, followed by cardiovascular events and neoplasms. Twenty-
seven patients died of cancer, most often of malignancies of the gastrointestinal 
tract (n=7), haematological malignancies (n=5) and malignancies of the respiratory 
tract (n=4). Urinary bladder cancer caused only one death. The relative proportions 
of causes of death did not differ much between the two decades (Figure 8). 
*All patients had been diagnosed with WG during their lifetime, but in 4 patients 
the underlying cause of death was recorded as rheumatoid arthritis (n=2), systemic 
lupus erythematosus (n=1) or vasculitis (n=1). 
p for linearity 0.028
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Figure 8. causes of death of Wegener’s granulomatosis patients by 10-year periods.
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No significant difference in mortality existed between patients in the earlier and 
those in the later 10-year period (gender- and age-adjusted hazard ratio 0.89 [95% 
CI: 0.64 to 1.24]) (Figure 9).
Figure 9: age- and sex-adjusted survival of Wegener’s granulomatosis patients in the two 10-year periods. 
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No significant difference in mortality existed between women and men (age-adjusted 
hazard ratio 1.11 [95% CI = 0.84 to 1.47]). The standardized mortality ratio (SMR) 
for all wG patients diagnosed in 1981-2000 was 3.43 (95% CI = 2.98 to 3.94), 
4.38 (95% CI = 3.59 to 5.61) for women and 2.80 (95% CI = 2.28 to 3.41) for men 
(Table 17, Figure 10).
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Table 17. Proportions of patients surviving one, three and five years after diagnosis of Wegener’s 
granulomatosis, grouped by gender and 10-year period of diagnosis.
1981-1990 1991-2000
Male 1-year survival, % (95% ci) 84.8 (72.7-91.8) 80.4 (73.9-85.5)
3-year survival, % (95% ci) 81.4 (68.9-89.2) 73.9 (67.0-79.7)
5-year survival, % (95% ci) 78.0 (65.1-86.6) 70.6 (63.5-76.7)
Female 1-year survival, % (95% ci) 85.1 (74.0-91.7) 84.1 (77.9-88.6)
3-year survival, % (95% ci) 80.6 (68.9-88.2) 80.2 (73.7-85.3)
5-year survival, % (95% ci) 73.1 (60.8-82.1) 76.4 (69.5-81.9)
all 1-year survival, % (95% ci) 84.9 (77.4-90.1) 82.2 (77.9-85.8)
3-year survival, % (95% ci) 81.0(72.9-86.8) 77.1 (72.4-81.0)
5-year survival, % (95% ci) 75.4 (66.9-82.0) 73.5 (68.7-77.7)
Figure 10. age-adjusted survival of male and female Wegener’s granulomatosis patients with 95% 
confidence intervals.
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No marked improvements in the treatment of wG took place in the 1980s and 
1990s. Rather similar treatment schemes prevailed, CyC and GCs being the favourite 
drugs. Prognosis remained constant; in fact, the prognosis seemed to be poorer in 
the later decade (Table 17). After adjustment for age and gender, the difference 
disappeared. Men and women lived equally long after the diagnosis of wG. However, 
if not for wG, women would outlive men by many years. This explains women’s 
considerably higher SMR.
In the 1970s and 1980s, rapid strides occurred in the development of therapies 
for wG and other vasculitides, and prognosis improved markedly (Fauci et al. 1983). 
The survival results of the present study concur fairly well with other published data 
(Mahr  et al. 2001, Koldingsnes et al. 2002. Bligny et al. 2004). 
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5.7.4. progNoStiC fACtorS
Along with mortality, factors with an impact on mortality of wG patients were 
analysed. Risk of dying increased with increasing age, and also elevated serum 
creatinine levels at diagnosis predicted poorer prognosis. Patients with initial ENT 
involvement had a considerably better prognosis than those without. Treatment 
with CyC had an independently positive effect on survival. Male or female gender 
was not a marked risk. In the initial phase, i.e. during the first six months of wG-
related symptoms, men had significantly more renal symptoms (p=0.014) and more 
pulmonary and constitutional symptoms. Diagnostic delay, fulfilling ACR criteria, 
high ELK score or high ESR at diagnosis had no impact on mortality from wG, 
although any one of these factors could be considered to be indicative of a more 
severe and/or widespread disease. It can be hypothesized that the prompt use of 
CyC, which has an independently favourable impact on prognosis, explains this 
phenomenon, at least partly (Table 18).  
The overall survival of dialysed wG patients seemed to be as good as that of non-
dialyed patients. Although no significant difference emerged between the groups, in 
looking at survival curves, the dialysed patients had an initial 1- to 2-year period of 
excessive mortality. Patients dying during the first two years after dialysis perished 
most often (57%) due to the disease process of wG itself and in; 24% died due to 
cardiovascular events. After the first couple of years, the mortality curves are more 
or less parallel (Figure 11).
ANCA-positivity in the year of wG diagnosis was associated with a better 
prognosis than ANCA-negativity. However, continuously ANCA-negative patients 
had a better prognosis than those even once ANCA-positive (Figure 12 a & b). ANCA-
positive and ANCA-negative patients had malignancies equally often (p=0.52).
we can only speculate about the connection of ANCA with survival. If a patient 
was tested initially and found to be ANCA-positive, he/she was probably treated 
promptly and properly and had a better prognosis than an ANCA-negative patient 
(Figure 12 a). However, if a patient was constantly negative for ANCA, the prognosis 
would be even better. (Figure 12 b). 
In several other studies (Mahr et al. 2001, Koldingsnes et al. 2002, Bligny et 
al. 2004, Pavone et al. 2006), poorer survival with advancing age and developing 
renal insufficiency has been shown. The disease course of permanently ANCA-
negative patients appears to be more restricted and milder (Fienkielman et al. 
2007; Gomez-Puerta et al. 2009
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Table 18. age- and gender-adjusted hazard ratios (hRs) for individual factors affecting survival of patients 
with Wegener’s granulomatosis
variable hR (95% ci) p-value
gender, male 1.11 (0.84 to 1.47) 0.46
age, years 1.07 (1.06 to 1.08) <0.001
diagnostic delay, months 0.16†
 <6 1.00 (reference)
 6-11 1.06 (0.70 to 1.62)
 12-23 0.90 (0.57 to 1.43)
 ≥24 1.37 (0.97 to 1.93)
acR criteria ≥2 1.02 (0.71 to 1.46) 0.92
symptoms within 6 months of onset
 kidney 1.05 (0.79 to 1.40) 0.72
 ent 0.70 (0.53 to 0.93) 0.014
 Pulmonary 0.98 (0.73 to 1.30) 0.87
 constitutional 0.77 (0.58 to 1.03) 0.074
serum creatinine level at diagnosis 0.011†
 i tertile (≤89 µmol/l) 1.00 (reference)
 ii tertile (90-180 µmol/l)  1.32 (0.87 to 2.00)
 iii tertile (≥181 µmol/l  ) 1.68 (1.13 to 2.50)
cyclophosphamide used 0.64 (0.47 to 0.87) 0.004
acR: american college of Rheumatology
elk score (0-3): number of organ systems (ear, nose and throat; lung; kidney) 
simultaneously involved
ent: ear, nose and throat
esR: erythrocyte sedimentation rate
† test for linearity (between tertiles)
Figure 11. survival of dialysed and non-dialyzed Wg patients.
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Figure 12. survival of patients based on anca.
a) ANCA examined in the year of wG diagnosis
 
b) ANCA examined at any time during the course of the disease
 Thus, our data do not support the possibility that ANCA-negative patients  have 
underlying malignancies and that their vasculitis is in fact paraneoplastic. 
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The survival of dialysed patients was as good as that of non-dialyzed patients, at 
least after the initial 1-2 years (Figure 9). Patients with kidney transplants seemed 
to survive even better than the rest of wG patients and better than the rest of 
dialysed wG patients. If the patient coped with the first fulminant phase of the 
disease and the vasculitis process had mostly receded, the chances for survival 
were fairly good. Moreover, patients must have been in remission for long, i.e. the 
disease process virtually extinguished, before they were considered for a kidney 
transplantation. Thus, transplanted patients were in clinical remission from the 
disease, and therefore, their prognosis was good. After transplantation, patients 
are on continuous immunosuppressive medication to preclude the rejection of the 
transplant. Immunosuppression may also preclude recurrence of vasculitis.  
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6. GENERAL DISCUSSION
wG remains an uncommon disease, although its incidence has increased markedly. 
wG has serious consequences; diagnosis probably means years on medication with 
potential numerous side-effects, frequent visits to hospital wards and outpatient 
departments, repeated laboratory tests, risk of renal insufficiency (often dialysis-
dependent) and risk of increased mortality rate. Because of the complexity and 
variety of its presentation and the often insidious progress, the recognition of 
wG calls for the  vigilance and cooperation of several specialties in medicine. 
Vague persisting constitutional symptoms and musculoskeletal aches and pains 
may finally lead to referral to a rheumatologist; cutaneous vasculitides are seen 
by dermatologists; refractory adult otitis or sinusitis calls for an ENT specialist; 
pulmonary examinations start after prolonged cough or alarming haemoptysis. All 
of these situations may arouse suspicions, and wG may be revealed. ENT physicians 
often have a key role in diagnostics because wG most frequently begins in their field. 
Fairly often, patient’s first contact may be with an ophthalmologist or a dermatologist 
for their symptoms. 
Recognition of wG has improved constantly in recent decades along with 
developments in diagnostic means, as discussed previously. In particular, the 
introduction of ANCA tests into diagnostic use has improved recognition of wG 
and related vasculitides. C-ANCA and especially PR3-ANCA are very specific to 
wG, whereas p-ANCA and MPO-ANCA are typical of MPA. These subclasses are 
useful in differential diagnosis of ANCA vasculitides, although some overlapping 
in  specificity occurs. The initial phases and localized forms of wG in patients with 
vague and unspecific symptoms are the most difficult to diagnose. These patients 
also tend to remain ANCA-negative, and therefore tests do not support the diagnosis. 
The incidence of wG has increased, at least partly because of improved 
recognition, but the growth seems to have ceased since 1996. The awareness of 
wG among  physicians may have reached a stand-still and perhaps diagnostic 
means have not improved further. Recent figures may therefore represent the true 
incidence of wG.    
This study, like several previous ones, shows that wG is a disease warranting 
early recognition and treatment. The prognosis of wG has greatly improved since the 
1930s and 1950s along with developments in the treatment regimens. Nowadays, the 
diagnosis of wG is not the death sentence that it used to be in the 1950s and 1960s. 
During the two-decade survey period, the treatment regimen remained constant, 
as were the results and survival rates. Thus, the results are reliable and they can 
be generalized. Biological agents have, at least theoretically, advantages over 
traditional medications. The great challenge in the treatment of wG, as well as of 
63
other autoimmune diseases, is to suppress selectively the autoimmune reaction 
responsible for the disease process. Treatment with cytotoxic agents and GCs leads 
to an overly extended immunosuppression, rendering the patient susceptible to 
infections and  perhaps malignancies.  Although the prognosis of wG patients has 
improved, morbidity and mortality are still a concern. The NIH treatment scheme 
(Fauci’s scheme) was revolutionary, but it can be associated with troublesome 
adverse effects, including increased risk of malignancies with elevated cumulative 
doses of CyC. The results in Finland in 1981-200 are in line with these findings. 
After realizing the risks, treatment strategies have been developed towards shorter 
courses and smaller total doses of CyC and other immunosuppressive therapies 
with wider safety profiles. After achieving remission, CyC medication is switched to 
MTX, AZA, leflunomide or MFF. These alternatives are similarly effective as CyC 
in remission maintenance. while, in general, they have fewer adverse effects than 
CyC, they are not without problems (see sections 3.5.4-5).    
 The discovery of biological targeted drugs and their great success in the treatment 
of inflammatory arthritides have raised interest and hope in their efficacy on 
vasculitides. Until now, treatment with biological agents has been far from targeted. 
They block or reduce the effect of inflammatory cytokines (TNFα, INFγ or IL-1) 
or reduce the number of cells producing mediators of inflammation (Lee 2008, 
Manna 2008, Ramos-Casals 2008, Lamprect 2009). Although some good results 
have been presented, these drugs seem to increase infectious complications without 
being effective in wG. Improved  knowledge of aetiology and disease mechanisms 
will allow better therapies to be  developed. Ideally, these would be therapies that 
treat the disease alone, without causing untoward harm. In this respect, rituximab 
has shown promising results,  especially in vasculitis-type wG with few adverse 
effects. It may provide a good treatment alternative, particularly for young patients. 
Although new treatment regimens have been developed during the past decades, 
CyC is still considered to be the cornerstone of medical therapy for wG. In a 
generalized disease, the medication is usually started with a combination of CyC 
and GC. MTX can be used in combination with GCs in non-organ-threatening or 
non-life-threatening generalized disease. After achieving remission, CyC medication 
may be switched to MTX, AZA, leflunomide or MFF.  The remission-maintenance 
therapy is continued for at least 18 months. If the disease is localized to the airways, 
trimethoprim-sulfamethoxazole  treatment can be used as a monotherapy or in 
combination with GC (and perhaps MTX), as both a remission-inducing and 
remission-maintenance therapy. In life- or organ-threatening disease, the remission-
inducing treatment can be complemented with methylprednisone pulses and/or 
plasmapheresis and/or intravenous immunoglobulin infusions (Bosch et al.2007, 
Ozaki et al. 2007, Mukhtyar et al. 2009, Pettersson et al. 2010).  
As might be expected, early recognition and intervention of wG are favourable 
for the prognosis of patients. This was not, however, shown in the present study. 
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In 1981-2000, while diagnostic delay decreased markedly, survival rate did not 
improve. Nonetheless, the results imply that CyC medication is favourable per se. 
The most critically ill are likely diagnosed much more rapidly, although their disease 
cannot be completely suppressed. The similar results in patients with full-blown 
disease and  those with mild, restricted disease speaks in favour of the efficacy of 
individually tailored treatment strategies.       
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7. SUMMARy AND CONCLUSIONS
The incidence of wG increased considerably in Finland in 1981-2000 probably for 
several reasons. The clinical picture of wG remained essentially the same during 
these two decades. Most often, the disease started with ENT (45%), pulmonary 
(36%) or constitutional symptoms (36%). The clinical picture tended to evolve 
into a more generalized form of a disease; in a minority of cases, wG remained in 
a localized form. 
The majority of wG patients were treated according to the “Fauci scheme” with 
CyC and GCs. The survival of wG patients has improved dramatically from the 
1950s and 1960s, but excess mortality still occurs compared with the rest of the 
population. The prognosis has not improved further in the 1980s and 1990s, and 
the serious adverse effects of the toxic medications are of great concern, calling for 
new treatment protocols.
At diagnosis of wG, 30% of patients had impending renal insufficiency. About in 
one- third of these patients, renal function recovered and dialysis was not needed. 
with wG treatment, 30% of the 84 patients needing dialysis regained their renal 
function, at least temporarily. Nineteen (3.9% of all wG patients) patients received 
a kidney transplant; sixteen of them were alive and not on dialysis at the end of 
the survey.  
This study, like several other recent studies, shows that wG is a disease 
warranting early recognition and treatment. The treatment results during the twenty 
years of the study are by far superior to those of the preceding decades.  
Strengths of this study are that the hospital discharge register covers the whole 
of Finland and that the hospital records of all patients with a discharge diagnosis 
of wG and treated at hospitals of specialized heath care were reviewed and their 
diagnoses confirmed.
A weakness of our study is that we included only patients treated at a hospital 
ward at least once. Information was gathered retrospectively from patient files and 
some information was probably missing. Also diagnostic criteria varied with district 
and time. we have probably missed some patients treated only at health centres 
who had a  limited form of the disease.
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